All In Biotech

NDA 219304 · Deciphera Pharms

Romvimza

Vimseltinib · Oral · Kinase Inhibitor

NovelPriority review

CDER novel approval, Feb 14, 2025: To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Feb 14, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

7

1 Phase 3, 2 recruiting

FAERS reports

549

85 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 26, 2026.

ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ROMVIMZA is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ( 1 )

Mechanism: Vimseltinib is a kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF1R). In vitro, vimseltinib inhibited CSF1R autophosphorylation, signaling induced by CSF1 ligand binding, and proliferation of cells expressing CSF1R.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ROMVIMZA · VIMSELTINIB 20MG · CAPSULE, ORAL · Prescription
  • ROMVIMZA · VIMSELTINIB 30MG · CAPSULE, ORAL · Prescription
  • ROMVIMZA · VIMSELTINIB 14MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vimseltinib" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue136
  • swelling face69
  • pruritus63
  • periorbital swelling60
  • peripheral swelling51
  • product use issue45
  • arthralgia42
  • nausea42
  • rash42
  • eye swelling40
  • headache39
  • product dose omission issue34

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
20221
2025313
2026233

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Deciphera Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.